. 2019 Oct 31;10(1):10. doi: 10.1186/s13317-019-0120-x

Table 3.

Expansion of autoantibody antigenic targets related to primary biliary cholangitis along follow-up

Target	Time^a	Groups
Target	Time^a	BN/AMA+ (n 59)	p	PBC (n 35)	p
Sp100^b	T₀	15 (25%)	0.097	4 (11%)	0.048
Sp100^b	T_X	19 (32%)	0.097	10 (29%)	0.048
Gp210^b	T₀	4 (7%)	1.000	3 (9%)	0.094
Gp210^b	T_X	4 (7%)	1.000	7 (20%)	0.094
CENP-A/CENP-B^b	T₀	0 (0%)	0.317	6 (17%)	0.317
CENP-A/CENP-B^b	T_X	1 (2%)	0.317	5 (14%)	0.317
PDC-E2/74 kDa-band^c	T₀	42 (71%)	0.053	32 (91%)	0.317
PDC-E2/74 kDa-band^c	T_X	48 (81%)	0.053	31 (87%)	0.317
56 kDa-band^c	T₀	3 (5%)	0.154	2 (6%)	0.074
56 kDa-band^c	T_X	5 (8%)	0.154	5 (14%)	0.074
52 kDa-band^c	T₀	25 (42%)	0.029	21 (60%)	1.000
52 kDa-band^c	T_X	31 (53%)	0.029	21 (60%)	1.000
48 kDa-band^c	T₀	6 (10%)	0.010	7 (20%)	0.094
48 kDa-band^c	T_X	12 (20%)	0.010	11 (31%)	0.094

BN/AMA+ biochemically normal individuals with positive AMA test, PBC patients with Primary Biliary Cholangitis

^aT₀ is the baseline sample; T_X is the sequential sample in which there was appearance of new autoantibody, which was variable among different individuals

^bDetermined by ELISA

^cDetermined by Western blot